Trifluorothymidine induces cell death independently of p53

I. V. Bijnsdorp, F. A. Kruyt, M. Fukushima, G. J. Peters*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Trifluorothymidine (TFT), a potent anticancer agent, inhibits thymidylate synthase (TS) and is incorporated into the DNA, both events resulting in cell death. Cell death induction related to DNA damage often involves activation of p53. We determined the role of p53 in TFT cytotoxicity and cell death induction, using, respectively, the sulforhodamine B-assay and FACS analysis, in a panel of cell lines with either wild type, inactive, or mutated p53. Neither TFT cytotoxicity nor cell death induction changed with TFT exposure in cell lines with wt, inactive or mutated p53. Conclusion: sensitivity to TFT is not dependent on the expression of wt p53.

Original languageEnglish
Pages (from-to)699-703
Number of pages5
JournalNucleosides, Nucleotides & Nucleic Acids
Volume27
Issue number6-7
DOIs
Publication statusPublished - 2008
Externally publishedYes
Event12th International Symposium on Purine and Pyrimidine Metabolism - Chicago, Israel
Duration: 24-Jun-200728-Jun-2007

Keywords

  • p53
  • trifluorothymidine
  • TAS-102
  • cell death
  • THYMIDYLATE SYNTHASE INHIBITION
  • COLON-CARCINOMA CELLS
  • ANTICANCER AGENTS
  • CANCER-CELLS
  • COMBINATION ANTIMETABOLITE
  • COLORECTAL-CANCER
  • APOPTOSIS
  • INDUCTION
  • MECHANISM

Cite this